The effects of Valette® on skin and hair: A post-marketing surveillance study

International Journal of Clinical Practice

Volumn 54, Issue 2, 2000, Pages

  Zimmermann, T ^a   Wisser, K H ^a   Dietrich, H ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; DRUG DERIVATIVE; ESTRADIOL DERIVATIVE; NANDROLONE;

ADOLESCENT; ADULT; ARTICLE; CONTRACEPTION; FEMALE; GERMANY; HAIR DISEASE; HUMAN; NORMAL HUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SCHOOL CHILD; SKIN DISEASE; DRUG EFFECT; HAIR; PATIENT COMPLIANCE; SKIN;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; GERMANY; HAIR; HUMANS; NANDROLONE; PATIENT COMPLIANCE; PRODUCT SURVEILLANCE, POSTMARKETING; SKIN;

EID: 0034150104     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Drife JO. The benefits and risks of oral contraceptives today, 2nd edn. London: Parthenon, 1996.
2. Elstein M. Present status of hormonal contraception (COCs). Adv Contracept 1996; 12: 155-166.
3. Oettel M, Carol W, Elger W et al. A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Drugs of Today 1995; 31(7): 517-536.
4. Elstein M, Furniss H. The fiction of an ideal contraceptive. Adv Contracept 1996; 12: 129-138.
5. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51(2): 188-215.
6. Böcker R, Kleingeist B. Influence of dienogest on the human cytochromc P450 enzyme system in vitro. In: Teichmann AT, Ed. Dienogest: preclinical and clinical features of a unique progestogen. New York: Walter de Gruyter, 1995; 14.
7. Juchem M, Schaffrath M, Pollow K et al. Dienogest: studies of binding to receptor and serum proteins. In: Teichmann AT, Ed. Dienogest: preclinical and clinical features of a unique progestogen. New York: Walter de Gruyter, 1995; 12.
8. Schleussner E, Michels W, Bethge S et al. Effect of dienogest on the hypothalamo-pituitary axis: a pilot study. In: Teichmann AT, Ed. Dienogest: preclinical and clinical features of a unique progestogen. New York: Walter de Gruyter, 1995; 17.
9. Spona J, Feichtinger W, Kindermann C et al. Modulation of ovarian function by an oral contraceptive containing 0.03 mg ethinyl estradiol in combination with 2.00 mg dienogest. Contraception 1997; 56: 185-191.
10. Spona J, Feichtinger W, Kindermann C et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system. Contraception 1997; 56: 67-75.
11. Hoffmann A, Reimann I, Nassr N et al. Pharmacokinetics of dienogest as a single agent and in combination with ethinyloestradiol. In: Teichmann AT, Ed. Dienogest: preclinical and clinical features of a unique progestogen. New York: Walter de Gruyter, 1995; 10.
12. Oettel M, Elger W, Golbs S et al. A 19-norprogestin without a 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view. Drugs of Today 1995; 31(7): 499-516.
13. Moore C, Klinger G, Walter F et al. Influence of MP 2000 on contraceptive efficacy, cycle stability and tolerance: pilot study in healthy women over 6 cycles. In: Teichmann AT, Ed. Dienogest: preclinical and clinical features of a unique progestogen. New York: Walter de Gruyter, 1995; 18.
14. Golbs S, Klinger G, Moore C et al. Clinico-chemical and haematological effects of MP 2000 after administration to healthy female subjects over 6 cycles, investigated within the scope of a phase III clinical trial. In: Teichmann AT, Ed. Dienogest: preclinical and clinical features of a unique progestogen. New York: Walter de Gruyter, 1995; 19.
15. Moore C, Feichtinger W, Kliuger G et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999; 35(suppl C): 53-58.
16. Hagen H, Hagen A, Lehnert W et al. Klinische Erfassung antiandrogener Effecte von Dienogest. In: Teichmann AT, Ed. Dienogest-Präklinik und Klinik eines Gestagens, 2 Auflage. Berlin & New York: Walter de Gruyter, 1995; 223-230.
17. Zimmermann T, Dietrich H, Wisser KH, Hoffmann H. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999; 35(suppl C): 79-88.
18. Luderschmidt C. Hormonal control of androgenic disorders in women. In: Elstein M, Ed. Extragenital effects of oral contraceptives. Fourth Congress of the European Society of Contraception, Barcelona, Spain, June 1996. Carnforth & New York: Parthenon, 1996; 45-51.
19. Corson SL. Contraceptive steroid effects on nonproductive organ systems. J Reprod Med 1986; 31(9, suppl): 865-878.
20. Archer DF. Clinical and metabolic features of desogestrel: a new oral contraceptive preparation. Am J Obstet Gynecol 1994; 170: 1550-1555.
21. Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinyl estradiol/desogestrel-containing oral contraceptive. Arzneimittelforschung 1988; 38: 932-934.
22. Weber-Diehl F, Unger R, Lachnit U. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception 1992; 46: 19-27.